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HIV-1 disrupts the homeostatic equilibrium between the host and coinfecting microbes, facilitating reactiva-
tion of persistent viruses and invasion by new viruses. These viruses usually accelerate HIV disease but occa-
sionally create conditions detrimental for HIV-1. Understanding these phenomena may lead to anti-HIV-1
strategies that specifically target interactions between HIV-1 and coinfecting viruses.Introduction: The Human Body as a Battlefield
of Microbes
The development of immunology in the last century led to the
concept of a healthy ‘‘germ-free’’ human body that repulses
and eliminates invading microbes by generating effective
immune reactions. Through the years, it became clear that
a healthy host is not germ free and does not always fight ‘‘germs’’
but may, rather, live in symbiotic relationships with some of
them. The concept of symbiosis between the host and microbes
was first accepted for bacteria (the ‘‘microbiome’’) and more
recently has been expanded to viruses (the ‘‘virome’’) (Virgin
et al., 2009). These germs shape many of the important aspects
of our physiology, including the immune system (Barton et al.,
2007; Mason et al., 2008; Unanue, 2007). Thus, the human
body can be viewed as a natural medium that not only provides
human microbes with space to maintain their genes, but is also
affected by them.
In a healthy human body, microbes live in a dynamic equilib-
rium with the host (Figure 1A). Each new invading microbe—in
particular, a virus (or viruses) —resets this balance in an attempt
to create favorable conditions for its own existence, leading to
beneficial or detrimental conditions for other microbes. In
response to some invading microbes, however, the host fails
to reset this equilibrium, and such microbes become pathogens.
From this perspective, the difference between ‘‘symbiotic’’ and
‘‘pathogenic’’ microbes is related to their ability to establish
a new equilibrium with the host rather than to inherited ‘‘patho-
genic’’ or ‘‘nonpathogenic’’ features. For a particular microbe,
this ability may also depend on the body compartment. Never-
theless, some microbes are never capable of establishing such
an equilibrium and are invariably harmful, whereas others are
harmless under most conditions. Because the establishment
of such an equilibrium is evolutionarily beneficial, human patho-
gens often become less pathogenic with time. This notion is
illustrated by the evolution of the primate lentiviruses. Simian
immunodeficiency virus (SIV), which has circulated in sooty
mangabeys (SIVsm) and African green monkeys (SIVagm) for
a long time, does not cause AIDS, despite high replication and
lack of immune control (Paiardini et al., 2009). SIV began to infect
chimpanzees (SIVcpz) more recently than sooty mangabeys or
African green monkeys, and it causes a disease, which is appar-
ently less severe than the one that human immunodeficiencyvirus type 1 (HIV-1) causes (Keele et al., 2009). The high patho-
genicity of HIV-1 is likely related to the fact that it is a relatively
new virus. Its invasion greatly imbalances the body’s equilibrium
with other microbes.
The human immune system responds to this invasion, leading
to a chronic state of immune activation that paradoxically
becomes the driving force of HIV-1 pathogenesis (Grossman
et al., 2006). At the same time, the immune system is impaired
by HIV and is no longer able to control the replication of
nonpathogenic symbiotic viruses or to prevent invasion by other
microbes (including bacteria ‘‘leaking’’ from a damaged gut)
(Brenchley et al., 2006).
The uncontrolled replication of the symbiotic and newly
invading microbes contributes to the imbalance of the immune
system by perpetuating its uncoordinated activation, which, in
turn, further accelerates progression toward AIDS (Figure 1B).
Thus, like an orchestra that after a sudden disappearance of
the conductor continues chaotically to play fragments of the
scored melodies, in HIV-1-infected individuals, the immune
system continues to play out a chaotic and ineffective attack
against microbes.
Below, we review mechanisms by which interactions between
HIV and other viruses lead to the imbalance of the immune
system in coinfected human host. Although bacteria, protozoa,
and fungi also play a role in HIV pathogenesis, we limit our review
to the interactions between HIV and coinfecting viruses.
HIV-1: A Virus that Never Comes Alone
HIV-induced disruption of the equilibrium between a human host
and its virome leads to two grave consequences: reactivation of
ubiquitous symbiotic viruses, which start to replicate to higher
levels, and infection by new viruses. In this imbalanced system,
both symbiotic viruses and the new invaders cause different
pathological conditions, including some ‘‘AIDS-defining’’ ones
(Virgin et al., 2009).
In the most general terms, the reactivation of symbiotic viruses
and the acquisition of new viral infections are consequent to the
impairment of the immune system (‘‘immunodeficiency’’). For
example, HIV-1 infection is associated with a 3-fold increase in
the frequencies of herpes simplex virus type 2 (HSV-2) anogen-
ital shedding (Schacker et al., 1998). Also, HIV-1 disease causes
loss of control of cytomegalovirus (CMV) and Epstein-Barr virusCell Host & Microbe 6, November 19, 2009 ª2009 Elsevier Inc. 403
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diseases and EBV-related lymphomas (Carbone et al., 2009;
Steininger, 2007). Likewise, in HIV-coinfected individuals,
defects in hepatitis C virus (HCV)-specific T cell responses are
the main causes of the higher HCV plasma load and altered
course of hepatitis C (Thein et al., 2008). Furthermore, in HIV-
infected individuals, the probabilities of human papilloma virus
(HPV) acquisition and of the development of intraepithelial
neoplasia increase in proportion to the loss of CD4 T cells (Strick-
ler et al., 2005). More examples can be listed (Masur and Kaplan,
2001).
Thus, commonly, the association of HIV-1 disease with other
viral diseases is explained by immunodeficiency. However,
such an account is too general and does not explain why viral re-
Figure 1. Host-Virus Equilibrium Is Disrupted by HIV-1
(A) Prior to HIV infection, the immune system of the immunocompetent host
establishes a dynamic equilibrium with symbiotic viruses, which are contained
by the immune response that they trigger. This response includes cell activa-
tion and cytokine production. Such a balanced immune system protects the
host from invading viruses.
(B) HIV infection disrupts the balance of the immune system, which now fails to
prevent the replication of symbiotic viruses and to contain invading viruses.
Uncontrolled replication of HIV and of these viruses further imbalances the
immune system by perpetuating uncoordinated responses. These responses
include aberrant cell activation and abnormal cytokine production, which, in
their turn, affect HIV replication, resulting in upregulation but, in some cases,
in suppression of HIV-1 infection.404 Cell Host & Microbe 6, November 19, 2009 ª2009 Elsevier Inc.activations or new infections sometimes occur before signs of
major immunodeficiency. More specific analysis of viral interac-
tions with each other and with the human host infected with HIV-
1 is needed to explain why HIV-1 disease is so closely associated
with infection by other microbes.
HIV-1 Coinfecting Viruses Contribute
to Immunodeficiency
Prior to HIV infection, the dynamic equilibrium between the
human virome and the immunocompetent host is determined
by the ability of the immune system to evoke effective responses
and the ability of persistent symbiotic viruses to evade them.
Mechanisms by which these viruses evade the immune
response include: (1) downregulation of MHC (e.g., by CMV-
encoded US2, 3, 6, and 11; human herpesvirus (HHV)-6- and
HHV-7-encoded UL-21); (2) induction of host cytokines (e.g., of
CXCL8, CCL5, CCL2, and IL-1 by CMV or EBV); (3) interference
with host cytokine signaling (e.g., TNF-a- and IFN-a-signaling
modulated by EBV or adenovirus); (4) expression of virus-en-
coded chemokine homologs (virokines) and chemokine recep-
tors (viroceptors) (e.g., EBV-encoded IL-10 homolog BCRF1,
CMV-encoded IL-10 homolog US111, HHV-6-encoded CCL5
homolog U83, and HHV-7-encoded b-chemokine receptor
homolog U12); (5) inhibition of apoptosis (e.g., by CMV-encoded
v-Bcl-2 homolog or EBV-encoded v-ICA and v-MIA); and (6)
altered activation of autologous complement (e.g., by modula-
tion of CD46 expression by HHV-6 and HHV-7) (Finlay and
McFadden, 2006; Lusso, 2006; Murphy, 2001).
In HIV disease, the high level of replication of symbiotic viruses
results in a high expression of the above mentioned and other
immune-modulating proteins encoded by these viruses. These
proteins that previously aimed to keep the immune response at
bay are now being produced in larger quantities and may signif-
icantly contribute to the immune dysfunction of the HIV-1-coin-
fected host. For example, the diversion of MHC I from the cell
surface by coinfecting viruses can favor the immune evasion
not only of these viruses, but also of HIV-1 itself. Similarly, the
production of virokine homologs of IL-10 may aggravate HIV-
1-induced immune dysfunctions. Newly invading viruses, in-
cluding those that have been acquired due to high-risk behavior,
may also contribute to immunodeficiency by signaling interfer-
ences, effector modulation, or continuous viral genetic variation
(Finlay and McFadden, 2006; Gale and Foy, 2005).
Thus, the immunodeficiency primarily caused by HIV results in
reactivation of coinfecting viruses and in new infections, further
impairing the immune system and thus leading to one of several
vicious cycles that fuel HIV disease (Figure 1).
HIV Coinfecting Viruses Contribute to Immunoactivation
Although the immune system imbalanced by HIV fails to build an
adequate immune response against HIV, the system is not at
a standstill. It responds to viral reactivations and new infections
with poorly coordinated but powerful elements of the previously
effective defense. Reactivated and newly invading viruses acti-
vate the CD4 T cells, which become new targets for HIV. This
state of chronic activation is considered to be the driving force
of HIV disease (Grossman et al., 2006) and defines another
vicious cycle in which coinfecting viruses and HIV-1 facilitate
each other’s infection. For example, HIV-1 infection promotes
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activated T cells that serve as new cell targets for HIV replication
(Van de Perre et al., 2008; Zhu et al., 2009). Likewise, in CMV/
HIV-1-coinfected individuals, the increase in the fraction of
specific CMV-activated T cells and the higher rate of T cell prolif-
eration in response to CMV are associated with accelerated CD4
T cell loss and progression to AIDS (Papagno et al., 2004; Schrier
et al., 1996; Waldrop et al., 1997). Similarly, HCV infection favors
activation of T cells (Gonzalez et al., 2009).
Thus, apparently, in HIV-1-infected patients, constant
attempts of the host to suppress previously controlled and newly
invading viruses, as well as HIV itself, lead to chronic cell immu-
noactivation. Such immunoactivation damages the immune
system by multiple mechanisms, including a reduced capacity
to generate responses to antigens, proliferative senescence of
T cells, and induction of proapoptotic and proinflammatory cyto-
kines (Sodora and Silvestri, 2008). Also, in HIV-infected individ-
uals, immune cell activation leads to an increase of viral replica-
tion due to expansion of the numbers of HIV-1 cell targets.
Another important element of coordinated immune responses
to viral infections in the immunocompetent host is the system of
chemokines/cytokines that are modulated to control newly
invading viruses. In HIV-1-infected individuals, the chemokine/
cytokine spectrum, which is already modulated in response to
HIV, is changed further upon new infections in a failed attempt
to control these viruses. For example, HHV-6 specifically upre-
gulates CCL5 (Grivel et al., 2001), whereas measles virus (MV),
human T lymphotropic virus type 2 (HTLV-2), and GB virus C
(GBV-C) infections increase the production of CCL5 together
with a variety of other cytokines, including CCL3 and CCL4
(Pilotti et al., 2007; Xiang et al., 2004). Similarly, in HCV/HIV-
coinfected patients, elevated levels of TGF-b and reduced levels
of TNF-a, CXCL8, and IL-10 have been demonstrated (Low et al.,
2008). In the genital tract, HPV and HSV-2 interfere with the
secretion of several cytokines (Ellermann-Eriksen, 2005; Sancle-
mente and Gill, 2002). The effect of an imbalanced chemokine/
cytokine system on HIV disease is difficult to study because of
the complexity and redundancy of this system and also because
of the additional effects of virokines and viroceptors. For
example, HHV-6 encodes both the virokine UL83A, which binds
to CCR5, and the viroceptor U51, which may act as ‘‘chemokine
sink’’ for CCL5 (Milne et al., 2000; Murphy, 2001), whereas CMV
US28 viroceptor offers an additional coreceptor for HIV-1 (Plesk-
off et al., 1997).
Other viral proteins may shortcut the host immune response
and directly affect HIV-1 transcription by trans-activating HIV-1
LTR or by interfering with Tat functions. Viral proteins capable of
LTR trans-activation have been identified in the HTLV-1, HHV-6,
CMV, JC virus (JCV), and HSV genomes. On the other hand,
HIV-1-encoded proteins may also affect coinfecting viruses.
HIV-1 Nef effect on the switch of IgA and IgG2 can alter the repli-
cation of invading viruses; the HIV Tat trans-activation of HPV long
control region results in an increased expression of HPV E6 and
E7 oncogenes (Kim et al., 2008; Xu et al., 2009) (Table 1).
HIV Suppression by Coinfecting Viruses: The Paradox
of a Complex System Imbalance
In HIV-infected individuals, immunodeficiency, paradoxically
combined with immunoactivation, is associated with viral reacti-vations and new infections that facilitate HIV disease. However,
the chaotic combination of uncoordinated immune responses
that are typical of HIV disease may create conditions under
which infections by other viruses are detrimental for HIV-1.
Indeed, a number of studies have reported on HIV-1 suppression
by coinfecting viruses both in vivo and in vitro. The list of these
viruses includes HHV-6 and HHV-7, GBV-C, MV, dengue virus,
and HTLV-2. In particular, acute MV infection decreases the
HIV-1 plasma load by 1.4 log10 in coinfected children (Moss
et al., 2009). Similarly, a decrease of HIV-1 plasma RNA by 2
log10 was reported in a case of acute dengue virus coinfection
(Watt et al., 2003). Also, GBV-C and HTLV-2 coinfections are
associated with a delayed progression to AIDS: GBV-C coinfec-
tion reduces the mortality rate 3-fold (Xiang et al., 2001). In
HTLV-2/HIV-1-coinfected patients, there was a higher preva-
lence of long-term nonprogressors than in HIV-1 singly infected
patients (13.5% versus 1%) (Turci et al., 2006).
HIV-suppressing conditions can be created by various mech-
anisms. For example, JCV-encoded agnoprotein acts as a nega-
tive regulator of the activity of Tat and thus is capable of inhibiting
HIV-1 replication (Kaniowska et al., 2006; Stettner et al., 2009).
Also, GBV-C and dengue-encoded protein NS5 inhibit HIV repli-
cation in vitro (McLinden et al., 2008). Upregulation of CCR5-
binding chemokines CCL3, CCL4, and CCL5 seems to mediate
HIV-1 suppression by GBV-C (Xiang et al., 2004), MV (Grivel
et al., 2005), HTLV-2 (Pilotti et al., 2007), and HHV-6 (Grivel
et al., 2001).
However,at least in thecaseofHHV-6, a prolonged upregulation
of CCR5-binding chemokines in vivo selects for the CCL5-resis-
tant lentivirus variants (Biancotto et al., 2009). CCL5 resistance,
including the emergence of highly pathogenic CXCR4-utilizing
HIV-1 variants, is associated with the late stages of HIV disease.
This association may explain how HHV-6, in spite of the ability to
suppress HIV-1 infection, constitutes a cofactor in HIV disease
progression (Lusso and Gallo, 1995).
Table 1. Mechanisms of Interactions between HIV-1
and Coinfecting Viruses
Mechanisms Viruses
Immunoactivation HCV, HSV-2, CMV,
EBV, HTLV-2a
HIV-1 trans-activation HSV-2, HTLV-1, JCVa
Abnormal production of chemokines HTLV-1, HHV-6,
HTLV-2, MV, GBV-C
CD4, CCR5, or CXCR4 downregulation HHV-7, GBV-C
Expression of virokines and viroceptors CMV, HHV-6, HHV-7
Blockage of CD4 T cell cycle MV
Modulation of cytokine signaling EBV, adenovirus
Inhibition of apoptosis CMV, EBV
Aberrant activation of autologous
complement
HHV-6, HHV-7
MHC downregulation CMV, HHV-6, HHV-7
Note that a coinfecting virus may interact with HIV-1 through multiple
mechanisms. In contrast to other viruses, HTLV-2, HHV-6, HHV-7,
GBV-C, and MV, were reported to suppress HIV infection.
a Unlike other listed viruses, HTLV-2 reduces immune activation, and JCV
suppresses HIV-1 transactivation.Cell Host & Microbe 6, November 19, 2009 ª2009 Elsevier Inc. 405
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arise from the diminished expression of the main HIV cellular
receptor, CD4. Recently, downregulation of CD4 on memory
T cells has been described in African green monkeys as one of
possible contributors to their resistance to SIV disease (Beaum-
ier et al., 2009). A diminished CD4 expression has been reported
for HHV-7 infection of human lymphoid tissues ex vivo. In these
tissues, CD4 is downregulated not only in HHV-7-infected cells,
but also in bystander (uninfected) CD4 T lymphocytes, making
this effect massive. As a result, in HHV-7-coinfected human
tissues, HIV-1 is suppressed (Lisco et al., 2007). In vivo, such
an effect may modulate the CD4 T cell infectability by HIV.
Finally, the decrease in the number of cells that support effi-
cient HIV infection can be another mechanism of the suppres-
sion of HIV-1. In a simple way, these cells may be just killed or
blocked in their cell cycle, as reported for MV infection (Moss
et al., 2002, 2009), or, in a more complex process, cells may
diminish their activation as reported for HIV-1/HTLV-2-coinfec-
tion (Toro et al., 2005).
Most probably, the mechanisms described above (Table 1)
constitute only small components of a complex and not yet
understood system of interviral interactions, resulting in the facil-
itation of HIV infection or, more rarely, in its suppression. Under-
standing why HIV suppression prevails in some coinfections,
whereas coinfection upregulates HIV in other cases requires
a deciphering of the entire system of HIV interactions with other
viruses in coinfected hosts.
Lessons Learned from Coinfecting Microbes:
Implication for HIV-1 Therapy
Current strategies for treating viral infections are based on the
direct targeting of unique enzymes that play critical roles in the
viral cycle (e.g., HIV-1 reverse transcriptase, integrase, and
protease; hepatitis B virus (HBV); and HHV DNA polymerases)
or on the host factors that are essential for viral entry and replica-
tion (e.g., CCR5 inhibitors).
Knowledge of the mechanisms of interviral interaction may
lead to the development of new anti-HIV-1 strategies in which
the network of HIV interactions with other viruses in the coin-
fected host is targeted. Results of several recent studies suggest
that such a strategy against HIV-1 can be developed.
As mentioned above, HIV-1 pathogenesis is characterized by
a paradoxical coexistence of immunodeficiency and immunoac-
tivation. The unleashed replication of reactivated viruses acti-
vates immune cells in an attempt to contain such replication,
thus providing new targets for HIV. Because this vicious cycle
apparently contributes to HIV-1 disease progression, it is
conceivable to develop therapeutic interventions that target
those viral infections that lead to immune activation. In particular,
suppression of the replication of coinfecting symbiotic viruses
(e.g., EBV or CMV) independently of their clinical manifestation
may decrease HIV-1 load by diminishing immunoactivation. In
agreement with these considerations, recent studies showing
that recruitment of specific anti-HSV-2 T cells is critical for
HIV-1 infection suggest that the prevention of this recruitment
could be used as an anti-HIV strategy (Zhu et al., 2009). Earlier,
a similar approach to the suppression of HIV was proposed for
nonviral microbes that cause immunoactivation in HIV-1-in-
fected patients (intestinal bacteria, helminthes, and mycobacte-406 Cell Host & Microbe 6, November 19, 2009 ª2009 Elsevier Inc.ria) (Chang and Altfeld, 2009; Patel et al., 2004; Walson et al.,
2009).
Another strategy for the suppression of HIV-1 could be based
on a fine-tuning of replication of the ubiquitous HHV-6 and
HHV-7, which, in tissues ex vivo, suppress HIV-1 by increasing
the level of CCL5 or decreasing the level of CD4 (Grivel et al.,
2001; Lisco et al., 2007). It is conceivable that identification of
viral proteins mediating these biological effects will lead to the
design of molecules able to decrease the availability of receptors
and/or coreceptors for HIV-1 (Vermeire et al., 2007). In a similar
strategy, GBV-C protein NS5A was suggested to be developed
into an anti-HIV drug (McLinden et al., 2008).
Furthermore, knowledge of interviral interactions is crucial to
preventing undesired effects of antiviral agents and to exploiting
their beneficial synergies. Indeed, some drugs originally devel-
oped against non-HIV-1 viruses have a direct anti-HIV-1 activity
and, therefore, may be beneficial to coinfected individuals. For
example, lamivudine is active against both HBV and HIV-1.
Double-HBV/HIV targeting has also been described for enteca-
vir, emtricitabine, and tenofovir (Nunez and Soriano, 2005).
Therefore, strict guidelines have been developed in order to
maximize the advantages of the double-targeted antivirals
and to prevent selection of cross-resistant HIV or HBV variants
(Nunez and Soriano, 2005).
More recently, it was reported that an old antiherpetic drug,
acyclovir, is able to suppress not only HSV-2 DNA polymerase,
but also HIV-1 reverse transcriptase (Lisco et al., 2008). This
effect is mediated by phosphorylation of acyclovir by coinfecting
HHVs. The beneficial effect of acyclovir in the suppression of
HIV in HHV-coinfected individuals has now to be considered.
However, as with lamivudine and entecavir, the possible emer-
gence of HIV variants that could be cross-resistant to other
licensed antiretroviral drugs should be considered as well
(Nunez and Soriano, 2005; Tchesnokov et al., 2009).
In conclusion, detailed knowledge of host-mediated interac-
tions between viruses of the human virome and HIV is necessary,
not only for our understanding of complex basic mechanisms of
HIV infection, but also for the development of new anti-HIV ther-
apies. Knowledge of these interactions is also necessary for
vaccine studies because such interactions may have contributed
to the enhanced HIV-1 susceptibility among people vaccinated
against HIV with adenoviral vectors (Corey et al., 2009). A new
system biology approach may become helpful to describe the
complex network of interactions between various viruses, in
particular between HIV and other viruses in coinfected tissues.
Systematic investigation of these interactions may result in the
creation of a ‘‘Periodic Table of Microbes’’ (Margolis, 2003),
which like the Periodic Table of Elements, will predict the effects
of viruses on each other in the complex context of human body.
REFERENCES
Barton, E.S., White, D.W., Cathelyn, J.S., Brett-McClellan, K.A., Engle, M.,
Diamond, M.S., Miller, V.L., and Virgin, H.W., IV. (2007). Herpesvirus latency
confers symbiotic protection from bacterial infection. Nature 447, 326–329.
Beaumier, C.M., Harris, L.D., Goldstein, S., Klatt, N.R., Whitted, S., McGinty,
J., Apetrei, C., Pandrea, I., Hirsch, V.M., and Brenchley, J.M. (2009). CD4
downregulation by memory CD4+ T cells in vivo renders African green
monkeys resistant to progressive SIVagm infection. Nat. Med. 15, 879–885.
Cell Host & Microbe
Short ReviewBiancotto, A., Grivel, J.C., Lisco, A., Vanpouille, C., Markham, P.D., Gallo,
R.C., Margolis, L.B., and Lusso, P. (2009). Evolution of SIV toward RANTES
resistance in macaques rapidly progressing to AIDS upon coinfection with
HHV-6A. Retrovirology 6, 61.
Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S.,
Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., et al. (2006). Microbial
translocation is a cause of systemic immune activation in chronic HIV infection.
Nat. Med. 12, 1365–1371.
Carbone, A., Cesarman, E., Spina, M., Gloghini, A., and Schulz, T.F. (2009).
HIV-associated lymphomas and gamma-herpesviruses. Blood 113, 1213–
1224.
Chang, J.J., and Altfeld, M. (2009). TLR-mediated immune activation in HIV.
Blood 113, 269–270.
Corey, L., McElrath, M.J., and Kublin, J.G. (2009). Post-step modifications for
research on HIV vaccines. AIDS 23, 3–8.
Ellermann-Eriksen, S. (2005). Macrophages and cytokines in the early defence
against herpes simplex virus. Virol. J. 2, 59.
Finlay, B.B., and McFadden, G. (2006). Anti-immunology: evasion of the host
immune system by bacterial and viral pathogens. Cell 124, 767–782.
Gale, M., Jr., and Foy, E.M. (2005). Evasion of intracellular host defence by
hepatitis C virus. Nature 436, 939–945.
Gonzalez, V.D., Falconer, K., Blom, K.G., Reichard, O., Morn, B., Laursen, A.L.,
Weis, N., Alaeus, A., and Sandberg, J.K. (2009). High levels of chronic immune
activation in the T cell compartments of patients coinfected with hepatitis C
virus and human immunodeficiency virust type 1 and on highly active antiretro-
viral therapy are reverted by alpha interferon and ribavirin treatment. J Virol. 83,
11407–11411.
Grivel, J.C., Ito, Y., Faga, G., Santoro, F., Shaheen, F., Malnati, M.S., Fitzger-
ald, W., Lusso, P., and Margolis, L. (2001). Suppression of CCR5- but not
CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat. Med.
7, 1232–1235.
Grivel, J.C., Garcia, M., Moss, W.J., and Margolis, L.B. (2005). Inhibition of
HIV-1 replication in human lymphoid tissues ex vivo by measles virus. J. Infect.
Dis. 192, 71–78.
Grossman, Z., Meier-Schellersheim, M., Paul, W.E., and Picker, L.J. (2006).
Pathogenesis of HIV infection: what the virus spares is as important as what
it destroys. Nat. Med. 12, 289–295.
Kaniowska, D., Kaminski, R., Amini, S., Radhakrishnan, S., Rappaport, J.,
Johnson, E., Khalili, K., Del Valle, L., and Darbinyan, A. (2006). Cross-interac-
tion between JC virus agnoprotein and human immunodeficiency virus type 1
(HIV-1) Tat modulates transcription of the HIV-1 long terminal repeat in glial
cells. J. Virol. 80, 9288–9299.
Keele, B.F., Jones, J.H., Terio, K.A., Estes, J.D., Rudicell, R.S., Wilson, M.L., Li,
Y., Learn, G.H., Beasley, T.M., Schumacher-Stankey, J., et al. (2009).
Increased mortality and AIDS-like immunopathology in wild chimpanzees
infected with SIVcpz. Nature 460, 515–519.
Kim, R.H., Yochim, J.M., Kang, M.K., Shin, K.H., Christensen, R., and Park,
N.H. (2008). HIV-1 Tat enhances replicative potential of human oral keratino-
cytes harboring HPV-16 genome. Int. J. Oncol. 33, 777–782.
Lisco, A., Grivel, J.C., Biancotto, A., Vanpouille, C., Origgi, F., Malnati, M.S.,
Schols, D., Lusso, P., and Margolis, L.B. (2007). Viral interactions in human
lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-
tropic human immunodeficiency virus type 1 via CD4 modulation. J. Virol.
81, 708–717.
Lisco, A., Vanpouille, C., Tchesnokov, E.P., Grivel, J.C., Biancotto, A., Bricha-
cek, B., Elliott, J., Fromentin, E., Shattock, R., Anton, P., et al. (2008). Acyclovir
is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected
human tissues. Cell Host Microbe 4, 260–270.
Low, E., Vogel, M., Rockstroh, J., and Nelson, M. (2008). Acute hepatitis C in
HIV-positive individuals. AIDS Rev. 10, 245–253.
Lusso, P. (2006). HHV-6 and the immune system: mechanisms of immunomo-
dulation and viral escape. J. Clin. Virol. 37 (Suppl 1), S4–S10.
Lusso, P., and Gallo, R.C. (1995). Human herpesvirus 6 in AIDS. Immunol.
Today 16, 67–71.Margolis, L. (2003). Cytokines–strategic weapons in germ warfare? Nat.
Biotechnol. 21, 15–16.
Mason, K.L., Huffnagle, G.B., Noverr, M.C., and Kao, J.Y. (2008). Overview of
gut immunology. Adv. Exp. Med. Biol. 635, 1–14.
Masur, H., and Kaplan, J. (2001). Current status of opportunistic infections in
patients with HIV infection in the era of highly active antiretroviral therapy.
Curr. Clin. Top. Infect. Dis. 21, 64–82.
McLinden, J.H., Stapleton, J.T., Chang, Q., and Xiang, J. (2008). Expression of
the dengue virus type 2 NS5 protein in a CD4(+) T cell line inhibits HIV replica-
tion. J. Infect. Dis. 198, 860–863.
Milne, R.S., Mattick, C., Nicholson, L., Devaraj, P., Alcami, A., and Gompels,
U.A. (2000). RANTES binding and down-regulation by a novel human herpes-
virus-6 beta chemokine receptor. J. Immunol. 164, 2396–2404.
Moss, W.J., Ryon, J.J., Monze, M., Cutts, F., Quinn, T.C., and Griffin, D.E.
(2002). Suppression of human immunodeficiency virus replication during acute
measles. J. Infect. Dis. 185, 1035–1042.
Moss, W.J., Scott, S., Ndhlovu, Z., Monze, M., Cutts, F.T., Quinn, T.C., and
Griffin, D.E. (2009). Suppression of human immunodeficiency virus type 1 viral
load during acute measles. Pediatr. Infect. Dis. J. 28, 63–65.
Murphy, P.M. (2001). Viral exploitation and subversion of the immune system
through chemokine mimicry. Nat. Immunol. 2, 116–122.
Nunez, M., and Soriano, V. (2005). Management of patients co-infected with
hepatitis B virus and HIV. Lancet Infect. Dis. 5, 374–382.
Paiardini, M., Pandrea, I., Apetrei, C., and Silvestri, G. (2009). Lessons learned
from the natural hosts of HIV-related viruses. Annu. Rev. Med. 60, 485–495.
Papagno, L., Spina, C.A., Marchant, A., Salio, M., Rufer, N., Little, S., Dong, T.,
Chesney, G., Waters, A., Easterbrook, P., et al. (2004). Immune activation and
CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol.
2, E20.
Patel, A., Patel, K., Patel, J., Shah, N., Patel, B., and Rani, S. (2004). Safety and
antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for
antiretroviral-naive patients in India who are coinfected with tuberculosis
and HIV-1. J. Acquir. Immune Defic. Syndr. 37, 1166–1169.
Pilotti, E., Elviri, L., Vicenzi, E., Bertazzoni, U., Re, M.C., Allibardi, S., Poli, G.,
and Casoli, C. (2007). Postgenomic up-regulation of CCL3L1 expression in
HTLV-2-infected persons curtails HIV-1 replication. Blood 109, 1850–1856.
Pleskoff, O., Treboute, C., Brelot, A., Heveker, N., Seman, M., and Alizon, M.
(1997). Identification of a chemokine receptor encoded by human cytomega-
lovirus as a cofactor for HIV-1 entry. Science 276, 1874–1878.
Sanclemente, G., and Gill, D.K. (2002). Human papillomavirus molecular
biology and pathogenesis. J. Eur. Acad. Dermatol. Venereol. 16, 231–240.
Schacker, T., Zeh, J., Hu, H.L., Hill, E., and Corey, L. (1998). Frequency of
symptomatic and asymptomatic herpes simplex virus type 2 reactivations
among human immunodeficiency virus-infected men. J. Infect. Dis. 178,
1616–1622.
Schrier, R.D., Wiley, C.A., Spina, C., McCutchan, J.A., and Grant, I. (1996).
Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC
Group. HIV Neurobehavioral Research Center. J. Clin. Invest. 98, 731–740.
Sodora, D.L., and Silvestri, G. (2008). Immune activation and AIDS pathogen-
esis. AIDS 22, 439–446.
Steininger, C. (2007). Clinical relevance of cytomegalovirus infection in
patients with disorders of the immune system. Clin. Microbiol. Infect. 13,
953–963.
Stettner, M.R., Nance, J.A., Wright, C.A., Kinoshita, Y., Kim, W.K., Morgello,
S., Rappaport, J., Khalili, K., Gordon, J., and Johnson, E.M. (2009). SMAD
proteins of oligodendroglial cells regulate transcription of JC virus early and
late genes coordinately with the Tat protein of human immunodeficiency virus
type 1. J. Gen. Virol. 90, 2005–2014.
Strickler, H.D., Burk, R.D., Fazzari, M., Anastos, K., Minkoff, H., Massad, L.S.,
Hall, C., Bacon, M., Levine, A.M., Watts, D.H., et al. (2005). Natural history and
possible reactivation of human papillomavirus in human immunodeficiency
virus-positive women. J. Natl. Cancer Inst. 97, 577–586.Cell Host & Microbe 6, November 19, 2009 ª2009 Elsevier Inc. 407
Cell Host & Microbe
Short ReviewTchesnokov, E.P., Obikhod, A., Massud, I., Lisco, A., Vanpouille, C., Bricha-
cek, B., Balzarini, J., McGuigan, C., Derudas, M., Margolis, L., et al. (2009).
Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Muta-
tion in Reverse Transcriptase. J. Biol. Chem. 284, 21496–21504.
Thein, H.H., Yi, Q., Dore, G.J., and Krahn, M.D. (2008). Natural history of hepa-
titis C virus infection in HIV-infected individuals and the impact of HIV in the era
of highly active antiretroviral therapy: a meta-analysis. AIDS 22, 1979–1991.
Toro, C., Bassani, S., Rios, P., Jimenez, V., Camino, N., and Soriano, V. (2005).
Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive
patients. J. Clin. Virol. 32, 338–339.
Turci, M., Pilotti, E., Ronzi, P., Magnani, G., Boschini, A., Parisi, S.G., Zipeto,
D., Lisa, A., Casoli, C., and Bertazzoni, U. (2006). Coinfection with HIV-1
and human T-Cell lymphotropic virus type II in intravenous drug users is asso-
ciated with delayed progression to AIDS. J. Acquir. Immune Defic. Syndr. 41,
100–106.
Unanue, E.R. (2007). Viral infections and nonspecific protection–good or bad?
N. Engl. J. Med. 357, 1345–1346.
Van de Perre, P., Segondy, M., Foulongne, V., Ouedraogo, A., Konate, I., Hur-
aux, J.M., Mayaud, P., and Nagot, N. (2008). Herpes simplex virus and HIV-1:
deciphering viral synergy. Lancet Infect. Dis. 8, 490–497.
Vermeire, K., Lisco, A., Grivel, J.C., Scarbrough, E., Dey, K., Duffy, N., Marg-
olis, L., Bell, T.W., and Schols, D. (2007). Design and cellular kinetics of
dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modu-
lating activity. Biochem. Pharmacol. 74, 566–578.
Virgin, H.W., Wherry, E.J., and Ahmed, R. (2009). Redefining chronic viral
infection. Cell 138, 30–50.408 Cell Host & Microbe 6, November 19, 2009 ª2009 Elsevier Inc.Waldrop, S.L., Pitcher, C.J., Peterson, D.M., Maino, V.C., and Picker, L.J.
(1997). Determination of antigen-specific memory/effector CD4+ T cell
frequencies by flow cytometry: evidence for a novel, antigen-specific homeo-
static mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99,
1739–1750.
Walson, J.L., Herrin, B.R., and John-Stewart, G. (2009). Deworming helminth
co-infected individuals for delaying HIV disease progression. Cochrane Data-
base Syst. Rev., CD006419.
Watt, G., Kantipong, P., and Jongsakul, K. (2003). Decrease in human immu-
nodeficiency virus type 1 load during acute dengue fever. Clin. Infect. Dis. 36,
1067–1069.
Xiang, J., George, S.L., Wunschmann, S., Chang, Q., Klinzman, D., and Staple-
ton, J.T. (2004). Inhibition of HIV-1 replication by GB virus C infection through
increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 363, 2040–
2046.
Xiang, J., Wunschmann, S., Diekema, D.J., Klinzman, D., Patrick, K.D.,
George, S.L., and Stapleton, J.T. (2001). Effect of coinfection with GB virus
C on survival among patients with HIV infection. N. Engl. J. Med. 345, 707–714.
Xu, W., Santini, P.A., Sullivan, J.S., He, B., Shan, M., Ball, S.C., Dyer, W.B.,
Ketas, T.J., Chadburn, A., Cohen-Gould, L., et al. (2009). HIV-1 evades
virus-specific IgG2 and IgA responses by targeting systemic and intestinal B
cells via long-range intercellular conduits. Nat. Immunol. 10, 1008–1017.
Zhu, J., Hladik, F., Woodward, A., Klock, A., Peng, T., Johnston, C., Reming-
ton, M., Magaret, A., Koelle, D.M., Wald, A., et al. (2009). Persistence of HIV-1
receptor-positive cells after HSV-2 reactivation is a potential mechanism for
increased HIV-1 acquisition. Nat. Med. 15, 886–892.
